Year: 2023
Type: editorial
Abstract: Novel signaling pathways and therapy in breast cancerBreast cancer is the most common malignancy in women worldwide.Advances in breast cancer prevention and treatment have achieved a 90% five-year overall survival rate (1).However, a large number of patients with breast cancers recur over time, sometimes many decades after the initial diagnosis.Although there are multiple treatment options for breast cancer including endocrine therapy, chemotherapy, molecular targeted therapy, radiotherapy, and immunotherapy, there are still more than 40,000 breast cancer-related deaths annually in the US.Therefore, investigating molecular mechanisms of tumor progression, resistance and metastasis are crucial to better understand and identify atrisk patients and develop novel targets and treatment strategies in order to improve breast cancer patient prognosis and outcomes.The goals of this Research Topic were to highlight research into the molecular mechanisms underlying cancer progression in patients with breast cancer.This Research Topic aimed to focus on identifying novel intrinsic and extrinsic molecular pathways.We emphasized research with potential clinical applications either identifying at-risk patients for failing standard therapy approaches or targeting novel signaling pathways with a promise of novel therapeutics.There are two basic research studies that focused on transcription factor E2F family.One study, Zhang explored the role of polymerase delta 2 (POLD2) in triple-negative breast cancer (TNBC).They found a high expression of POLD2 in TNBC compared to normal tissue as well as other subtypes of breast cancer.Further, high expression of POLD2 was associated with poor prognosis in TNBC patients.This finding was supported by experimental data showing that knockdown of POLD2 inhibited cell proliferation in TNBC cells.As a mechanism, they elucidated that a transcription factor, E2F1, regulates POLD2 expression by directly binding to the POLD2 promoter.A second study, Zheng et al. examined E2F8 role in a basal-like subtype of breast cancer by bioinformatical and experimental approaches.They found that E2F8 expression was associated with poor prognosis in a basal-like breast cancer.E2F8 was associated with dysregulated cell cycle and Frontiers in Oncology frontiersin.
Source: Frontiers in Oncology
Authors: Eriko Katsuta, Mateusz Opyrchal
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,295
Funder: National Cancer Institute
OpenAlex ID: W4376891175